Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRAMBLE: Microtransplantation for AML
NCT02189824Phase 1Unknown
- Sponsor
- University of Sydney
- Start
- Aug 2014
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial in acute myeloid leukemia (AML), sponsored by University of Sydney. Primary endpoint: Acute Graft Versus Host Disease at 60 days. Status: unknown.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02189824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02189824.